RxDoctor Payments Data

Efrain Torres, MD

Geriatric Medicine · New Bedford, MANPI 1003859265

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $692, more than ten times the $26 reported in 2019.

$882in general payments, 2019–2025

Across 44 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$175
  • AstraZeneca$99
  • Viatris Specialty LLC$87
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$73
  • Verona Pharma, Inc.$63
  • AbbVie$53
  • plus $332 from 11 others

What the payments were for

  • Food & beverage$882100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$882 in reported general payments places this provider in the 85th percentile of 156 geriatric medicine providers in Massachusetts.

See all geriatric medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$452,655
Medicare patients
778
Services billed
4,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,201$394,811
JanuviaSitagliptin Phosphate439$178,841
JardianceEmpagliflozin362$151,717
TrulicityDulaglutide117$110,766
TradjentaLinagliptin253$76,976
XareltoRivaroxaban208$54,954
LinzessLinaclotide83$52,293
XifaxanRifaximin30$44,151
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog247$42,647
RexultiBrexpiprazole40$37,226
Breo ElliptaFluticasone/Vilanterol82$33,270
Atorvastatin Calcium2,137$25,986
Trazodone Hcl2,265$22,424
Incruse ElliptaUmeclidinium Bromide76$20,689
Mirtazapine836$20,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$394,8111,201 claims
Lilly USA, LLCTrulicity$175$110,766117 claims
Johnson & JohnsonXarelto$51$54,954208 claims
AbbVieLinzess$53$52,29383 claims
AstraZenecaFarxiga, Symbicort$99$32,064105 claims
Novo NordiskOzempic$51$18,85620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 156 geriatric medicine providers in Massachusetts.

Other geriatric medicine in New Bedford

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →